Teriparatide [PTH(1-34)] strengthens the proximal femur of ovariectomized nonhuman primates despite increasing porosity.
about
Systemically administered bone morphogenetic protein-6 restores bone in aged ovariectomized rats by increasing bone formation and suppressing bone resorptionBone health and associated metabolic complications in neuromuscular diseasesLack of bone neoplasms and persistence of bone efficacy in cynomolgus macaques after long-term treatment with teriparatide [rhPTH(1-34)].Expression of Rho GDIalpha in rat osteoblasts intermittently exposed to parathyroid hormone in vitro and in vivoEffects of intravenous zoledronic acid plus subcutaneous teriparatide [rhPTH(1-34)] in postmenopausal osteoporosis.Are osteoclasts needed for the bone anabolic response to parathyroid hormone? A study of intermittent parathyroid hormone with denosumab or alendronate in knock-in mice expressing humanized RANKL.Effect of sequential treatments with alendronate, parathyroid hormone (1-34) and raloxifene on cortical bone mass and strength in ovariectomized rats.The effect of PTH(1-34) on fracture healing during different loading conditions.Specimen size and porosity can introduce error into microCT-based tissue mineral density measurementsEarly changes in biochemical markers of bone turnover and their relationship with bone mineral density changes after 24 months of treatment with teriparatidebeta-Arrestin2 regulates the differential response of cortical and trabecular bone to intermittent PTH in female miceAnabolic agents and bone qualityInhibition of cathepsin K increases modeling-based bone formation, and improves cortical dimension and strength in adult ovariectomized monkeys.Molecular and cellular mechanisms of the anabolic effect of intermittent PTHImaging the femoral cortex: thickness, density and mass from clinical CT.Acute development of cortical porosity and endosteal naïve bone formation from the daily but not weekly short-term administration of PTH in rabbit.Effect of denosumab on bone mineral density and biochemical markers of bone turnover: 8-year results of a phase 2 clinical trialFemoral bone strength and its relation to cortical and trabecular changes after treatment with PTH, alendronate, and their combination as assessed by finite element analysis of quantitative CT scans.Bone quality and osteoporosis therapy.Effects of anti-osteoporosis medications on fracture healing.Co-administration of antiresorptive and anabolic agents: a missed opportunity.Parathyroid hormone and its receptor gene polymorphisms: implications in osteoporosis and in fracture healing.Effects of combination treatment with alendronate and raloxifene on skeletal properties in a beagle dog model.Individual and combined effects of noise-like whole-body vibration and parathyroid hormone treatment on bone defect repair in ovariectomized mice.Protein kinase inhibitor γ reciprocally regulates osteoblast and adipocyte differentiation by downregulating leukemia inhibitory factor.A novel quercetin analogue from a medicinal plant promotes peak bone mass achievement and bone healing after injury and exerts an anabolic effect on osteoporotic bone: the role of aryl hydrocarbon receptor as a mediator of osteogenic action.Hip and spine strength effects of adding versus switching to teriparatide in postmenopausal women with osteoporosis treated with prior alendronate or raloxifene.¹⁸F-fluoride PET as a noninvasive imaging biomarker for determining treatment efficacy of bone active agents at the hip: a prospective, randomized, controlled clinical study.Abaloparatide, a novel PTH receptor agonist, increased bone mass and strength in ovariectomized cynomolgus monkeys by increasing bone formation without increasing bone resorption.Denosumab rapidly increases cortical bone in key locations of the femur: a 3D bone mapping study in women with osteoporosis.A naturally occurring rare analog of quercetin promotes peak bone mass achievement and exerts anabolic effect on osteoporotic bone.Changes in the contents of enzymatic immature, mature, and non-enzymatic senescent cross-links of collagen after once-weekly treatment with human parathyroid hormone (1-34) for 18 months contribute to improvement of bone strength in ovariectomized mIn vivo discrimination of hip fracture with quantitative computed tomography: results from the prospective European Femur Fracture Study (EFFECT).Effect of intermittent treatment with human Parathyroid Hormone 1-34 in SAMP6 senescence-accelerated mice.Age-dependent variations of cancellous bone in response to ovariectomy in C57BL/6J mice.Bone grafts and biomaterials substitutes for bone defect repair: A review.Influence of Dosing Interval and Administration on the Bone Metabolism, Skeletal Effects, and Clinical Efficacy of Parathyroid Hormone in Treating Osteoporosis: A Narrative Review
P2860
Q24294642-EAE9260D-3397-4CA7-9BBB-FF701213481CQ27025688-D93CD47B-4342-4F80-9C82-736AB57AF405Q33358285-3E8842AA-1B61-4817-8B49-88BCD5010EB4Q33477862-4637AF11-E400-46A2-8671-EB2FF64EAA59Q34023772-A58140B0-2F7C-4E87-810D-6792CEC7CC1BQ34107428-239C3000-6959-4BAF-9E69-52BB4200EC06Q34149279-969E22CC-9480-40FA-94C0-505763F76A68Q34667582-5C4EDCF4-BFED-443D-AB19-4A56F6A1C093Q34862539-C2122076-81EE-4BB8-BDE2-F38DA0A9A313Q34975945-C63C8ABC-7BAE-4F74-B008-DFCA93731879Q35062148-C5E38F39-B7A2-4BF0-AD59-08A1E10F528CQ35078764-93927589-2F83-4231-A95C-A9490C6C7CDCQ35109866-B6A0E25B-A6AC-4B4D-8BBB-88A0347419F1Q36016775-CF39CBAB-5129-48D1-8D4C-5B10D00484E6Q36158343-62CEF7FA-5D56-4CC4-B622-7C101090D43AQ36342143-AD70EDC1-2208-42BC-BE9B-701FEFAC45B8Q36508404-CE18AF92-99DB-4317-A66B-DE9E1CD33094Q37203457-4C6C0E5B-3CAF-46E5-9080-EDC26DF70DA6Q37756589-0684125C-6AFF-4305-8EBC-B7115CA3A363Q37893520-DD8FF3D5-7E8F-408A-B28C-8FBDF7E8199DQ38367370-3CBC8A4E-DC52-4A0A-BCF9-46802E118C8AQ38550930-875F842D-C299-4BF0-B306-9C17A33AE552Q38632055-C98F6A96-2072-4D7D-89F9-48761E890860Q40299570-A66A0DC6-1DF6-46AA-B7B7-1F274DB0E589Q41969070-2B3BAA78-A2B9-4C5D-85ED-90CA795EC2C9Q43608666-3582E9F1-1128-4206-BF01-7D727E41BFBDQ44491077-C1D6146A-A2E4-49BE-81BA-162691638AC5Q46162569-B3E05581-07DE-484A-8495-016107DE7A26Q47232860-0635A3CE-9C72-4DAA-8AA8-DDFCE1D375E9Q51123246-EBA76A17-5E60-415A-B7D3-017876EF77F2Q51517961-FF2E18FC-F05C-46C4-9259-1CEE262DF9D2Q51536719-DB92D0E4-CCF9-45FD-B4C5-4EE6A17EC08DQ51538105-D07A43A1-3102-4BDA-8927-2F6D46684BB0Q51603425-35F46A7A-5ECC-4481-8104-7CD96D3C91F4Q55062269-8C3C5816-284E-4B09-90FB-4BB851E3FB35Q55285137-3E6D3F31-0CC4-4262-92B8-27D777D4B272Q57153285-5CAC8F68-C385-4409-86A8-A672E63C5DE7
P2860
Teriparatide [PTH(1-34)] strengthens the proximal femur of ovariectomized nonhuman primates despite increasing porosity.
description
2004 nî lūn-bûn
@nan
2004年の論文
@ja
2004年学术文章
@wuu
2004年学术文章
@zh
2004年学术文章
@zh-cn
2004年学术文章
@zh-hans
2004年学术文章
@zh-my
2004年学术文章
@zh-sg
2004年學術文章
@yue
2004年學術文章
@zh-hant
name
Teriparatide [PTH
@nl
Teriparatide [PTH(1-34)] stren ...... s despite increasing porosity.
@en
type
label
Teriparatide [PTH
@nl
Teriparatide [PTH(1-34)] stren ...... s despite increasing porosity.
@en
prefLabel
Teriparatide [PTH
@nl
Teriparatide [PTH(1-34)] stren ...... s despite increasing porosity.
@en
P2093
P356
P1476
Teriparatide [PTH(1-34)] stren ...... s despite increasing porosity.
@en
P2093
Allen Schmidt
Charles H Turner
Christopher P Jerome
Emmett V Glass
John Vahle
Masahiko Sato
Michael Westmore
Qing Q Zeng
Robert Brommage
Yanfei L Ma
P304
P356
10.1359/JBMR.040112
P577
2004-01-12T00:00:00Z